OVARIAN FUNCTION AND ADJUVANT CHEMOTHERAPY FOR BREAST CANCER
- 27 May 1978
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 311 (8074), 1159
- https://doi.org/10.1016/s0140-6736(78)90341-0
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The CMF program for operable breast cancer with positive axillary nodes:Updated analysis on the disease-free interval, site of relapse and drug toleranceCancer, 1977
- OVARIAN FUNCTION IN PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY FOR BREAST CANCERThe Lancet, 1977
- L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast CancerNew England Journal of Medicine, 1975
- Work in progress Menstrual induction with PGF2α and PGE2Prostaglandins, 1975
- Intrauterine injection of prostaglandin F2α for termination of early pregnancy in out-patientProstaglandins, 1974
- INTRAUTERINE PROSTAGLANDINS FOR OUTPATIENT TERMINATION OF VERY EARLY PREGNANCYThe Lancet, 1973
- The prospects of PGs in postconceptional therapyProstaglandins, 1973
- The efficacy and acceptability of the ″prostaglandin impact″ in inducing complete abortion during the second week after the missed menstrual periodProstaglandins, 1973
- Prophylactic oophorectomy in breast cancer therapy: A preliminary reportThe American Journal of Surgery, 1969
- The role of prophylactic castration in the therapy of human mammary cancerEuropean Journal of Cancer (1965), 1967